Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 2, 2009, Pages 163-171

  Yang, Yangfan ^a,b   Wu, Kaili ^a   Yuan, Hongzhi ^a   Yu, Minbin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; CYSTEINE DERIVATIVE; CYTOCHROME P450 2D6; PROXYMETACAINE; SERINE DERIVATIVE; THREONINE; TIMOLOL MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; TIMOLOL;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOTYPE; HEART RATE VARIABILITY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PHARMACOGENETICS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED DISORDER; GENETICS; HEART RATE; MIDDLE AGED; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BRADYCARDIA; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; TIMOLOL; YOUNG ADULT;

EID: 68149091499     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0028     Document Type: Article

References (41)

1. Zimmerman, T.J., and Kaufman, H.E. Timolol, a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 95:601-604, 1977. (Pubitemid 8263098)
2. Zimmerman, T.J., and Kaufman, H.E. Timolol, dose response and duration of action. Arch Ophthalmol. 95:605-607, 1977.
3. Zimmerman, T. J., and Boger, W.P. III. The beta-adrenergic blocking agents and the treatment of glaucoma. Surv. Ophthalmol. 23:347-362, 1979. (Pubitemid 9199790)
4. Boger, W.P. 3rd, Steinert, R.F., Puliafi to, C.A., et al. Clinical trial comparing timolol ophthalmic solution to pilocarpine in openangle glaucoma. Am. J. Ophthal. 86:9-18, 1978.
5. Bertram, J.P., Saluja, S.S., McKain, J., et al. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months. J. Microencapsul. 24:1-8, 2008.
6. Frishman, W.H., Kowalski, M., Nagnur, S., et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis. 3:386-397, 2001. (Pubitemid 34003379)
7. Meyer, N.I. Open-angle glaucoma and cardiovascular mortality. Ophthalmology. 114:392, 2007.
8. Abbott, A. With your genes? Take one of these, three times a day. Nature. 425:760-762, 2003. (Pubitemid 37351443)
9. Daly, A.K. Individualized drug therapy. Curr. Opin. Drug Discov. Dev. 10:29-36, 2007.
10. Shell, J.W. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 26:207-218, 1982.
11. Korte, J.M., Kaila, T., and Saari, K.M. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin. Exp. Ophthalmol. 240:430-435, 2002. (Pubitemid 36097063)
12. Nieminen, T., Lehtimäki, T., Mäenpää, J., et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J. Clin. Lab. Invest. 67:237-245, 2007. (Pubitemid 46410612)
13. Kaila, T., Huupponen, R., Karhuvaara, S., et al. Beta-blocking effects of timolol at low plasma concentrations. Clin. Pharmacol. Ther. 49:53-58, 1991.
14. Pelkonen, O., Mäenpää, J., Taavitsainen, P., et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 28:1203-1253, 1998. (Pubitemid 29017141)
15. Zanger, U.M., Raimundo, S., and Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369:23-37, 2004. (Pubitemid 38161221)
16. Gaedigk, A., Bhathena, A., Ndjountché, L., et al. Identifi cation and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 5:173-182, 2005. (Pubitemid 40852219)
17. Nieminen, T., Uusitalo, H., Mäenpää, J., et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. Eur. J. Clin. Pharmacol. 61:811-819, 2005. (Pubitemid 41720269)
18. Sachse, C., Brockmöller, J., Bauer, S., et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:284-295, 1997. (Pubitemid 27058401)
19. Gaedigk, A., Bradford, L.D., Alander, S.W., et al. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos. 34:563-569, 2006.
20. Soyama, A., Saito, Y., Komamura, K., et al. Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYP2D6*10 alleles. Drug Metab. Pharmacokin. 17:475-478, 2002.
21. Miglior, S., Zeyen, T., Pfeiffer, N., et al.; European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology. 112:366-375, 2005.
22. Edeki, T.I., He, H., Wood, A.J. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. J. Am. Med. Assoc. 274:1611-11163, 1995.
23. Ishii, Y., Nakamura, K., Tsutsumi, K., et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J. Clin. Pharmacol. 40:193-199, 2000.
24. Higginbotham, E.J. Topical beta-adrenergic antagonists and quinidine. A risky interaction. Arch. Ophthalmol. 114:745-746, 1996. (Pubitemid 26197010)
25. Szewczuk-Bogusławska, M., Kiejna, A., Grzesiak, M., et al. The infl uence of clomipramine on CYP2D6 activity. Psychiatr. Pol. 41:243-249, 2007. (Pubitemid 47074754)
26. Flammer, J., and Barth, D. Cardiovascular effects of local timolol therapy. Klin. Monatsbl. Augenheilkd. 176:561-565, 1980. (Pubitemid 10068783)
27. Groszmann, R.J., Garcia-Tsao, G., Bosch, J., et al.; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varies in patients with cirrhosis. N. Engl. J. Med. 353:2254-2261, 2005.
28. Sha, Q., Zhang, X., Zhu, X., et al. Analytical correction for multiple testing in admixture mapping. Hum. Hered. 62:55-63, 2006. (Pubitemid 44689371)
29. Tomalik-Scharte, D., Lazar, A., Fuhr, U., et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 8:4-15, 2008.
30. Caldwell, M.D., Berg, R.L., Zhang, K.Q., et al. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5:8-16, 2007. (Pubitemid 350218774)
31. Dorado, P., Berecz, R., Peñas-Lledó, E.M., et al. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin. Drug Metab. Toxicol. 3:9-19, 2007. (Pubitemid 47315416)
32. Ismail, R., and Teh, L.K. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J. Clin. Pharm. Ther. 31:99-109, 2006.
33. Kirchheiner, J., Henckel, H.B., Franke, L., et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics. 15:579-587, 2005. (Pubitemid 41044244)
34. Beverage, J.N., Sissung, T.M., Sion, A.M., et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J. Pharm. Sci. 96:2224-2231, 2007.
35. Chetty, M., and Murray, M. CYP-mediated clozapine interactions: how predictable are they? Curr. Drug Metab. 8:307-313, 2007. (Pubitemid 46780060)
36. Ozdemir, V., Bertilsson, L., Miura, J., et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonindopamine crosstalk revisited. Pharmacogenet. Genomics. 17:339-347, 2007. (Pubitemid 46608541)
37. Kaila, T., Huupponen, R., Karhuvaara, S., et al. Beta-blocking effects of timolol at low plasma concentrations. Clin. Pharmacol. Ther. 49:53-58, 1991.
38. Yin, O.Q., Shi, X.J., Tomlinson, B., et al. Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab. Dispos. 33:1383-1387, 2005. (Pubitemid 41196969)
39. Levo, A., Koski, A., Ojanperä, I., et al. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int. 135:9-15, 2003. (Pubitemid 36957845)
40. Fuchsjager-Mayrl, G., Markovic, O., Losert, D., et al. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol. Vis. 11:811-815, 2005. (Pubitemid 41410190)
41. Nieminen, T., Lehtimäki, T., Mäenpää, J., et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab. Invest. 67:237-245, 2007. (Pubitemid 46410612)